Glioblastoma and Stroke
Conditions
Interventions
Gold Standard:??Glioma??:
Histopathological diagnosis (2021 WHO CNS5) and Postoperative contrast-enhanced MRI (RANO criteria)+NGS
??Stroke??:
Emergency CT/MRI imaging (distinguishing ischemic/hemorrha
Index test:Liquid biopsy technology portfolio, including dPCR for detecting gene mutations and multi-time point cfDNA fragmentomics
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntary signing of a written informed consent form, age >= 18 years old, gender not restricted, KPS >=70. 2. For glioma, the postoperative pathological diagnosis must confirm it as glioma. Or it must be clinically diagnosed as hemorrhagic or ischemic stroke. 3. No treatment was received before the glioma surgery or before the admission for stroke. 4. There are no serious comorbidities or other major diseases that affect survival (such as severe heart disease, liver and kidney dysfunction, etc.). 5. Able to undergo regular follow-up during the study period, including outpatient follow-up and telephone follow-up.
Exclusion criteria
Exclusion criteria: 1. Individuals with severe mental illness or cognitive impairments. 2. Pregnant or lactating women. 3. Those with any other malignant tumors. 4. Those with any other history of neurological vascular diseases. 5. Those who have received or will receive other drug interventions during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concordance rate of liquid biopsy vs tissue mutations;AUC of multi-timepoint cfDNA for ischemic/hemorrhagic;Correlation between cfRNA dynamics and NIHSS improvement; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity of liquid biopsy in predicting recurrence; | — |
Countries
China
Contacts
Public ContactYing Mao
Huashan Hospital, Fudan University
Outcome results
None listed